Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

To be considered for this study, you would need to have muscle-invasive bladder cancer that has not spread to other parts of your body. Your doctors must confirm it's a specific type of bladder cancer, and you must be suitable for major surgery to remove your bladder and nearby lymph nodes.

A key requirement is that you either cannot receive cisplatin chemotherapy — perhaps due to kidney issues, certain heart conditions, significant hearing loss, or a lower energy level (ECOG performance status 2) — or you are eligible for cisplatin but have chosen not to have it. You also need to have generally good organ function and undergo a small procedure to remove some bladder tissue for testing.

Both men and women can participate, and there are specific requirements concerning contraception for men taking certain study drugs and for women who could become pregnant. All participants must be at least 18 years old.

If you join this study, it would involve a series of doctor's visits, medical checks, and possibly receiving study medication before and/or after your surgery. The type of surgery you would have is a standard operation to remove the bladder and surrounding lymph nodes. You would have regular check-ups, including scans and blood tests, to monitor your health and the cancer. The total duration of your participation would involve the treatment period and then a follow-up period to track your progress over time. More detailed information would be provided by the study team.